Teacher Retirement System of Texas Increases Position in Bristol Myers Squibb Company $BMY

Teacher Retirement System of Texas lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 16.2% during the third quarter, Holdings Channel reports. The institutional investor owned 1,208,368 shares of the biopharmaceutical company’s stock after purchasing an additional 168,780 shares during the period. Teacher Retirement System of Texas’ holdings in Bristol Myers Squibb were worth $54,497,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Probity Advisors Inc. purchased a new position in shares of Bristol Myers Squibb in the third quarter valued at about $317,000. Vanguard Capital Wealth Advisors lifted its holdings in Bristol Myers Squibb by 12.6% in the 3rd quarter. Vanguard Capital Wealth Advisors now owns 6,671 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 745 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Bristol Myers Squibb by 3.5% in the 3rd quarter. Parkside Financial Bank & Trust now owns 26,831 shares of the biopharmaceutical company’s stock worth $1,210,000 after purchasing an additional 898 shares during the period. iA Global Asset Management Inc. grew its holdings in Bristol Myers Squibb by 20.8% during the 3rd quarter. iA Global Asset Management Inc. now owns 158,680 shares of the biopharmaceutical company’s stock valued at $7,156,000 after buying an additional 27,347 shares in the last quarter. Finally, Ridgewood Investments LLC raised its position in shares of Bristol Myers Squibb by 18.7% during the third quarter. Ridgewood Investments LLC now owns 48,602 shares of the biopharmaceutical company’s stock valued at $2,192,000 after buying an additional 7,656 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $54.86 on Friday. The firm has a market capitalization of $111.68 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The business has a 50 day simple moving average of $52.41 and a 200-day simple moving average of $48.33. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. During the same period last year, the company earned $1.80 earnings per share. Bristol Myers Squibb’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be given a $0.63 dividend. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio is currently 85.14%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Large Janux oncology collaboration expands BMY’s cancer pipeline and gives access to an external asset with commercial potential — deal terms: up to ~$800–850M in payments, which strengthens BMY’s late-stage oncology roster and underpins near‑to‑midterm growth expectations. Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
• Positive Sentiment: Partnership with Microsoft to advance AI-driven early lung-cancer detection bolsters BMY’s diagnostics/R&D capabilities and supports longer-term, data-driven oncology strategy. Bristol Myers Squibb Announces Collaboration with Microsoft
• Positive Sentiment: New Opdivo use in early lung cancer is set for adoption in the UK — an approval/coverage expansion that can meaningfully increase immuno‑oncology sales in Europe. New Opdivo use in early lung cancer set for adoption in UK
• Positive Sentiment: Street bullishness: UBS and other firms are turning more positive on biotech/pharma recovery and BMY’s pipeline optionality, supporting sentiment and buy-side interest. UBS turns bullish as biotech and pharma show signs of a recovery
• Neutral Sentiment: Ongoing clinical updates: Bristol Myers updated an ongoing KarXT long-term safety study — data could move the share price when readouts arrive, but the immediate impact is informational until results are released. KarXT Safety Study: What Long-Term Urological Data Could Mean
• Negative Sentiment: Near-term estimate cut: An analyst lowered BMY’s Q1 EPS estimate, which weighs on short-term earnings expectations and adds caution for quarterly performance. Q1 EPS Estimate for Bristol Myers Squibb Lowered by Analyst
• Negative Sentiment: Small downward revisions to Q4 2026 EPS from Zacks Research highlight modest near-term volatility in quarterly figures despite longer-term guidance. (Analyst estimate shifts reported by market research services.)

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BMY. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Citigroup reiterated a “neutral” rating and issued a $53.00 target price (up from $45.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 7th. Wells Fargo & Company increased their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $56.86.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.